

				What is your role(s) in this CME/CPD: (check all that apply)						Relationship with commercial interest		Presenting or referencing therapeutic product
First Name	Last Name	Country	Session Title	Scientific/ Education Planning Committee	Poster/Oral Presenter	Board of Directors	Committee (CME, Research, other)	Session Moderator/ Chair/ Coordinator	Other (please specify)	Type of Relation	Company	Therapeutic product
Martin	Bennett	United Kingdom	Aging, dementia and stroke		Poster/Oral Presenter							
Giorgio	Sesti	Italy	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter							
Patrick	Schrauwen	Netherlands	Environment and cardiovascular risk		Poster/Oral Presenter							
Minna	Kaikkonen-Maatta	Finland	Saag session 11: How cells talk? Smooth muscle cells and macrophages		Poster/Oral Presenter							
Minna	Kaikkonen-Maatta	Finland	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter							
Irene	Lang	Austria	Saag session 25: Immunity and atherosclerosis - getting to the roots					Session Moderator/Chair/Coordinator		Honoraria/Expenses	Janssen	
Irene	Lang	Austria	Atherothrombosis and myeloid cells					Session Moderator/Chair/Coordinator		Honoraria/Expenses	Janssen	
Irene	Lang	Austria	Saag session 25: Immunity and atherosclerosis - getting to the roots							Honoraria/Expenses	AOPOrphan Pharma	
Irene	Lang	Austria	Atherothrombosis and myeloid cells							Honoraria/Expenses	AOPOrphan Pharma	
Irene	Lang	Austria	Saag session 25: Immunity and atherosclerosis - getting to the roots							Honoraria/Expenses	MSD	
Irene	Lang	Austria	Atherothrombosis and myeloid cells							Honoraria/Expenses	MSD	
Irene	Lang	Austria	Saag session 25: Immunity and atherosclerosis - getting to the roots							Honoraria/Expenses	Neutrolis	
Irene	Lang	Austria	Atherothrombosis and myeloid cells							Honoraria/Expenses	Neutrolis	

Carlo	Patrono	Italy	Atherothrombosis and myeloid cells		Poster/Oral Presenter					Honoraria/Expenses	Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Eli Lilly, Tremeau and Zambon; he chairs the Scientific Advisory Board of the International Aspirin Foundation.	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)		Poster/Oral Presenter					Stock Options	Verve Therapeutics	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)							Stock Options	Maze Therapeutics	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)							Stock Options	Color Health	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)							Stock Options	Medgenome	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)							Consultant/Advisory Board	Medgenome	
Sekar	Kathiresan	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)							Consultant/Advisory Board	Color Health	
Michael	Roden	Germany	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter							
Bart	van de Sluis	Netherlands	Apo B containing lipoproteins		Poster/Oral Presenter							
Michael	Blaha	United States of America	Imaging guided management		Poster/Oral Presenter					Consultant/Advisory Board	Amgen	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Sanofi	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Regeneron	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Novartis	

Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Novo Nordisk	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Bayer	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Akcea	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	89Bio	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Kaleido	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Inozyme	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Roche	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	Kowa	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	VoxelCloud	
Michael	Blaha	United States of America	Imaging guided management							Consultant/Advisory Board	emocha	
Michael	Blaha	United States of America	Imaging guided management							Funded Research	Amgen	
Michael	Blaha	United States of America	Imaging guided management							Funded Research	Bayer	
Alice	Lichtenstein	United States of America	Environment and cardiovascular risk		Poster/Oral Presenter							
Ira	Goldberg	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?		Poster/Oral Presenter					Honoraria/Expenses	Akcea	
Ira	Goldberg	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Arrowhead	

Amit	Khera	United States of America	Plenary 1: Personalised approach to ASVD: The future is here							Poster/Oral Presenter			Consultant/Advisory Board	Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Verve Therapeutics, Silence Therapeutics, Veritas International, Color Health, Third Rock Ventures	
Amit	Khera	United States of America	Plenary 1: Personalised approach to ASVD: The future is here										Funded Research	Novartis Institute for Biomedical Research and IBM Research.	
Amit	Khera	United States of America	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here									invited speaker	Honoraria/Expenses	AstraZeneca	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	Novartis	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	Amgen	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	Berlin-Chemie	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	Bristol-Myers Squibb	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Honoraria/Expenses	Sanofi	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here										Consultant/Advisory Board	AstraZeneca	

Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Novartis	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Amgen	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Pfizer	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	The Medicines Company	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	DalCor Pharmaceuticals	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Kowa	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Corvidia Therapeutics	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Genentech	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	OMEICOS	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Daiichi Sankyo	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Singulex	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Abbott	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Roche Diagnostics	
Wolfgang	Koenig	Germany	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Dr. Beckmann Pharma	
Manuel	Mayr	United Kingdom	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter					Consultant/Advisory Board	Multomics Health	
Kathryn	Moore	United States of America	Plenary 3: From lifestyle to designer therapies		Poster/Oral Presenter					Employee	Merck Research Laboratories	

Kathryn	Moore	United States of America	Plenary 3: From lifestyle to designer therapies							Stock Options	Merck Research Laboratories	
Kathryn	Moore	United States of America	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Beren Therapeutics	
Kathryn	Moore	United States of America	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Novartis	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?		Poster/Oral Presenter					Employee	Universite de Montreal	
Daniel	Gaudet	Canada	Late breaker session 1		Poster/Oral Presenter					Employee	Universite de Montreal	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches		Poster/Oral Presenter					Employee	Universite de Montreal	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Amgen	
Daniel	Gaudet	Canada	Late breaker session 1							Honoraria/Expenses	Amgen	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Amgen	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Arrowhead	
Daniel	Gaudet	Canada	Late breaker session 1							Honoraria/Expenses	Arrowhead	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Arrowhead	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Eli Lilly	
Daniel	Gaudet	Canada	Late breaker session 1							Honoraria/Expenses	Eli Lilly	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Eli Lilly	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Regeneron	
Daniel	Gaudet	Canada	Late breaker session 1							Honoraria/Expenses	Regeneron	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Regeneron	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Honoraria/Expenses	Verve Therapeutics	
Daniel	Gaudet	Canada	Late breaker session 1							Honoraria/Expenses	Verve Therapeutics	

Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Verve Therapeutics	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Amgen	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Amgen	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Amgen	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Arrowhead	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Arrowhead	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Arrowhead	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Eli Lilly	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Eli Lilly	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Eli Lilly	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Sanofi	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Sanofi	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Sanofi	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Regeneron	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Regeneron	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Regeneron	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Consultant/Advisory Board	Verve therapeutics	
Daniel	Gaudet	Canada	Late breaker session 1							Consultant/Advisory Board	Verve therapeutics	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Verve therapeutics	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Acasti	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Acasti	

Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Acasti	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Akcea	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Akcea	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Akcea	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Amgen	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Amgen	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Amgen	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Applied Therapeutics	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Applied Therapeutics	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Applied Therapeutics	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Arrowhead	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Arrowhead	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Arrowhead	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Astra Zeneca	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Astra Zeneca	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Astra Zeneca	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Boehringer-Ingelheim	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Boehringer-Ingelheim	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Boehringer-Ingelheim	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	CNRC	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	CNRC	



Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	CNRC	
Daniel	Gaudet	Canada	Plenary 2: Lipoproteins revisited: What has changed ?							Funded Research	Dalcor Pharma	
Daniel	Gaudet	Canada	Late breaker session 1							Funded Research	Dalcor Pharma	
Daniel	Gaudet	Canada	HOFH: new insights in therapeutic approaches							Funded Research	Dalcor Pharma	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)		Poster/Oral Presenter					Funded Research	Novartis	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?		Poster/Oral Presenter					Funded Research	Novartis	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)							Royalties/Patent	UCSD	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Royalties/Patent	UCSD	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)							Ownership/Equity Position	Oxitope Inc/Pharma	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Ownership/Equity Position	Oxitope Inc/Pharma	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)							Employee	Ionis	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Employee	Ionis	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)							Ownership/Equity Position	Kleanthi Diagnostics	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Ownership/Equity Position	Kleanthi Diagnostics	
Sotirios	Tsimikas	United States of America	Saag session 03: The many faces of Lp(a)							Ownership/Equity Position	Covicept Therapeutics	
Sotirios	Tsimikas	United States of America	Plenary 2: Lipoproteins revisited: What has changed ?							Ownership/Equity Position	Covicept Therapeutics	
Charalambos	Antoniades	United Kingdom	Plenary 3: From lifestyle to designer therapies		Poster/Oral Presenter							
Marie-Luce	Bochaton-Piallat	Switzerland	Saag session 12: Novel mechanisms in plaque stabilization		Poster/Oral Presenter							

Marie-Luce	Bochaton-Piallat	Switzerland	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter							
Jose	Fuster	Spain	Aging, dementia and stroke		Poster/Oral Presenter							
Chiara	Giannarelli	United States of America	Plenary 1: Personalised approach to ASVD: The future is here						Invited Speaker			
Bertrand	Cariou	France	PCSK9 – new insights		Poster/Oral Presenter					Funded Research	Amgen	
Bertrand	Cariou	France	PCSK9 – new insights							Funded Research	Regeneron	
Bertrand	Cariou	France	PCSK9 – new insights							Consultant/Advisory Board	Novartis	
Bertrand	Cariou	France	PCSK9 – new insights							Honoraria/Expenses	Amgen	
Bertrand	Cariou	France	PCSK9 – new insights							Honoraria/Expenses	Sanofi	
Julie	Redfern	Australia	Advanced clinical seminar: Changing face of atherosclerosis		Poster/Oral Presenter							
Joseph	Saseen	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic						Session Moderator/Chair/Coordinator			
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	Young fellows' session						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	Committee Disclosure						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	General Assembly						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	General Assembly						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Consultant/Advisory Board	Novartis	

Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	Young fellows' session							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	Committee Disclosure							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Novartis	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	Young fellows' session							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	Committee Disclosure							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Daiichi-Sankyo	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	Young fellows' session							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	Committee Disclosure							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Sobi	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Consultant/Advisory Board	Akcea	

Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	Young fellows' session							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	Committee Disclosure							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	General Assembly							Consultant/Advisory Board	Akcea	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	Young fellows' session							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	Committee Disclosure							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	General Assembly							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	General Assembly							Honoraria/Expenses	Amgen	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	Young fellows' session							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	Committee Disclosure							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	General Assembly							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	General Assembly							Honoraria/Expenses	Novartis	
Christoph	Binder	Austria	Plenary 3: From lifestyle to designer therapies							1	Technoclone	
Christoph	Binder	Austria	Modulating immune responses in atherosclerosis							1	Technoclone	

Christoph	Binder	Austria	Non-classical risk factors: Transitioning from association to causality							1	Technoclone	
Christoph	Binder	Austria	Young fellows' session							1	Technoclone	
Christoph	Binder	Austria	Committee Disclosure							1	Technoclone	
Christoph	Binder	Austria	General Assembly							1	Technoclone	
Christoph	Binder	Austria	General Assembly							1	Technoclone	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASD: The future is here	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	EAS Consensus activities	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	WHF Session 2: Global FH	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen
Kausik	Ray	United Kingdom	Committee Disclosure	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	Amgen

Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Late breaker session 1	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Poster Viewing session	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Amgen	

Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	General Assembly	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee	Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Amgen	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	EAS Consensus activities							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Funded Research	Daiichi Sankyo	

Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Committee Disclosure							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Late breaker session 1							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Poster Viewing session							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	General Assembly							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Daiichi Sankyo	



Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Funded Research	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	EAS Consensus activities							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Committee Disclosure							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Funded Research	Regeneron	

Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Late breaker session 1							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Poster Viewing session							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	General Assembly							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Funded Research	Regeneron	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Novartis	

Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Novartis	

Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Novartis	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Daiichi Sankyo	

Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Daiichi Sankyo	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Novo Nordisk	

Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Novo Nordisk	

Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Novo Nordisk	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Boehringer Ingelheim	

Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Boehringer Ingelheim	



Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	CSL Behring	

Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	CSL Behring	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Astra Zeneca	

Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Astra Zeneca	

Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Astra Zeneca	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Silence Therapeutics	

Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Silence Therapeutics	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Bayer	

Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Bayer	

Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Bayer	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Amgen	

Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Amgen	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Amgen	



Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Pfizer	

Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Pfizer	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Viatrix	

Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Viatrix	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Viatrix	

Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Viartis	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Viartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Viartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Viartis	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Lilly	

Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Lilly	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Boehringer Ingelheim	

Kausik	Ray	United Kingdom	EAS Consensus activities							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Committee Disclosure							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Late breaker session 1							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Poster Viewing session							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Honoraria/Expenses	Boehringer Ingelheim	

Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	General Assembly							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Honoraria/Expenses	Boehringer Ingelheim	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Novartis	

Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Novartis	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Kowa	



Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Reimagining population health- the time is now							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	Kowa	

Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Kowa	
Kausik	Ray	United Kingdom	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	EAS Consensus activities							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Consultant/Advisory Board	New Amsterdam	

Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Committee Disclosure							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Why and how to implement early combination lipid lowering therapy							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Reimagining population health-the time is now							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Late breaker session 1							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Poster Viewing session							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	National Society President Meeting (NSPM)							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	General Assembly							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	WHF Session 2: Global FH							Consultant/Advisory Board	New Amsterdam	

Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	New Amsterdam	
Kausik	Ray	United Kingdom	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	New Amsterdam	
Giuseppe Danilo	Norata	Italy	Debate session - HDL: In search for a function	Scientific/Education Planning Committee						Honoraria/Expenses	Sanofi	
Giuseppe Danilo	Norata	Italy	PCSK9 – new insights	Scientific/Education Planning Committee						Honoraria/Expenses	Sanofi	
Giuseppe Danilo	Norata	Italy	Committee Disclosure	Scientific/Education Planning Committee						Honoraria/Expenses	Sanofi	
Giuseppe Danilo	Norata	Italy	Debate session - HDL: In search for a function							Honoraria/Expenses	Novartis	
Giuseppe Danilo	Norata	Italy	PCSK9 – new insights							Honoraria/Expenses	Novartis	
Giuseppe Danilo	Norata	Italy	Committee Disclosure							Honoraria/Expenses	Novartis	
Giuseppe Danilo	Norata	Italy	Debate session - HDL: In search for a function							Honoraria/Expenses	Eli Lilly	
Giuseppe Danilo	Norata	Italy	PCSK9 – new insights							Honoraria/Expenses	Eli Lilly	
Giuseppe Danilo	Norata	Italy	Committee Disclosure							Honoraria/Expenses	Eli Lilly	
Giuseppe Danilo	Norata	Italy	Debate session - HDL: In search for a function							Honoraria/Expenses	Pfizer	
Giuseppe Danilo	Norata	Italy	PCSK9 – new insights							Honoraria/Expenses	Pfizer	
Giuseppe Danilo	Norata	Italy	Committee Disclosure							Honoraria/Expenses	Pfizer	
Lale	Tokgözoğlu	Turkey	Plenary 2: Lipoproteins revisited: What has changed ?	Scientific/Education Planning Committee					Session Moderator/Chair/Coordinator	1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	

Lale	Tokgözoğlu	Turkey	Keynote Lecture	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Lale	Tokgözoğlu	Turkey	Why and how to implement early combination lipid lowering therapy	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Lale	Tokgözoğlu	Turkey	EAS Consensus activities	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Lale	Tokgözoğlu	Turkey	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Lale	Tokgözoğlu	Turkey	NLA/EAS joint session - Primordial prevention: The neglected topic	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati

Lale	Tokgözoğlu	Turkey	Committee Disclosure	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	
Lale	Tokgözoğlu	Turkey	Why and how to implement early combination lipid lowering therapy	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	
Lale	Tokgözoğlu	Turkey	Reimagining population health- the time is now	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	
Lale	Tokgözoğlu	Turkey	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	
Lale	Tokgözoğlu	Turkey	National Society President Meeting (NSPM)	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati	

Lale	Tokgözoğlu	Turkey	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Lale	Tokgözoğlu	Turkey	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee				Session Moderator/Chair/Coordinator		1	Abbott, Actelion, Amgen, Bayer, Daiichi Sankyo, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati
Alberico L.	Catapano	Italy	Plenary 1: Personalised approach to ASVD: The future is here	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	Implementation of the 2019 lipid guidelines-where are we now?	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	EAS Consensus activities	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi



Alberico L.	Catapano	Italy	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	Committee Disclosure	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	EAS Consensus activities	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	National Society President Meeting (NSPM)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi

Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)	Scientific/Education Planning Committee		Board of Directors	Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Honoraria/Expenses	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi
Alberico L.	Catapano	Italy	Plenary 1: Personalised approach to ASVD: The future is here							1	Aegerion, Akcea, Amgen, Amryt, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Implementation of the 2019 lipid guidelines-where are we now?							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	EAS Consensus activities							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus



Alberico L.	Catapano	Italy	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Committee Disclosure							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	EAS Consensus activities							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	National Society President Meeting (NSPM)							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							1	Aegerion, Akcea, Amryt, Amgen, Astrazeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus

Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							1	Aegerion, Akcea, Amryt, Amgen, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceuticals, Kowa, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus



Alberico L.	Catapano	Italy	Plenary 1: Personalised approach to ASVD: The future is here							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Implementation of the 2019 lipid guidelines-where are we now?							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,

Alberico L.	Catapano	Italy	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	EAS Consensus activities							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,

Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Committee Disclosure							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,

Alberico L.	Catapano	Italy	EAS Consensus activities							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	
Alberico L.	Catapano	Italy	IME Session - Should public health recommendations target Lp(a) measurements?							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	

Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Industry Special Lecture (Not Included In The Main Event CME/CPD Credit)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	National Society President Meeting (NSPM)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,

Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,

Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	
Alberico L.	Catapano	Italy	Lipid Clinic Network National Coordinators Meeting (LCN)							Consultant/Advisory Board	Aegerion, Akcea, Amgen, Esperion, Daiichi Sankyo, Genzyme, Ionis Pharmaceuticals, Kowa, Menarini, Merck, Mylan, Novartis, Pfizer, Recordati, Regeneron, Sandoz, Sanofi,	
Katariina	Öörni	Finland	Apo B containing lipoproteins	Scientific/Education Planning Committee								

Katariina	Öörni	Finland	Free Communication 1 - Genetics of Dyslipidemia	Scientific/Education Planning Committee								
Katariina	Öörni	Finland	Committee Disclosure	Scientific/Education Planning Committee								
Winfried	Maerz	Austria	PCSK9 – new insights	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	AMGEN
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	AMGEN
Winfried	Maerz	Austria	Committee Disclosure	Scientific/Education Planning Committee	Poster/Oral Presenter				Session Moderator/Chair/Coordinator		Funded Research	AMGEN
Winfried	Maerz	Austria	PCSK9 – new insights								Funded Research	Sanofi
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver								Funded Research	Sanofi
Winfried	Maerz	Austria	Committee Disclosure								Funded Research	Sanofi
Winfried	Maerz	Austria	PCSK9 – new insights								Funded Research	Akzea Therapeutics
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver								Funded Research	Akzea Therapeutics
Winfried	Maerz	Austria	Committee Disclosure								Funded Research	Akzea Therapeutics
Winfried	Maerz	Austria	PCSK9 – new insights								Employee	Synlab Holding Deutschland GmbH
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver								Employee	Synlab Holding Deutschland GmbH
Winfried	Maerz	Austria	Committee Disclosure								Employee	Synlab Holding Deutschland GmbH
Winfried	Maerz	Austria	PCSK9 – new insights								Honoraria/Expenses	AMGEN
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver								Honoraria/Expenses	AMGEN
Winfried	Maerz	Austria	Committee Disclosure								Honoraria/Expenses	AMGEN
Winfried	Maerz	Austria	PCSK9 – new insights								Honoraria/Expenses	Sanofi



Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver							Honoraria/Expenses	Sanofi	
Winfried	Maerz	Austria	Committee Disclosure							Honoraria/Expenses	Sanofi	
Winfried	Maerz	Austria	PCSK9 – new insights							Honoraria/Expenses	Amryt Pharmaceuticals	
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver							Honoraria/Expenses	Amryt Pharmaceuticals	
Winfried	Maerz	Austria	Committee Disclosure							Honoraria/Expenses	Amryt Pharmaceuticals	
Winfried	Maerz	Austria	PCSK9 – new insights							Honoraria/Expenses	Abbott Diagnostics	
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver							Honoraria/Expenses	Abbott Diagnostics	
Winfried	Maerz	Austria	Committee Disclosure							Honoraria/Expenses	Abbott Diagnostics	
Winfried	Maerz	Austria	PCSK9 – new insights							Honoraria/Expenses	Novartis Pharma GmbH	
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver							Honoraria/Expenses	Novartis Pharma GmbH	
Winfried	Maerz	Austria	Committee Disclosure							Honoraria/Expenses	Novartis Pharma GmbH	
Winfried	Maerz	Austria	PCSK9 – new insights							Honoraria/Expenses	Daiichi-Sankyo	
Winfried	Maerz	Austria	Saag session 13: The culprit? Fatty liver							Honoraria/Expenses	Daiichi-Sankyo	
Winfried	Maerz	Austria	Committee Disclosure							Honoraria/Expenses	Daiichi-Sankyo	
Sanni	Söderlund	Finland	Committee Disclosure	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator		Employee	Helsinki and Uusimaa Hospital District	
Sanni	Söderlund	Finland	Committee Disclosure							Ownership/Equity Position	Terveystalo	
Sanni	Söderlund	Finland	Committee Disclosure							Ownership/Equity Position	Terveystalo	
Esther	Lutgens	Germany	Smooth muscle cell biology and plaque stability	Scientific/Education Planning Committee								
Esther	Lutgens	Germany	Committee Disclosure	Scientific/Education Planning Committee								
Mai-Lis	Hellenius	Sweden	NLA/EAS joint session - Primordial prevention: The neglected topic						Invited speaker			

Katey	Rayner	Canada	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter							
Antonio	Gotto	United States of America	Keynote Lecture		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Jeanine	Roeters van Lennep	Netherlands	Environment and cardiovascular risk					Session Moderator/Chair/Coordinator				
Jeanine	Roeters van Lennep	Netherlands	Poster Viewing session					Session Moderator/Chair/Coordinator				
Sanjay	Rajagopalan	United States of America	IAS/EAS joint session - What is the environment doing to our health?					Session Moderator/Chair/Coordinator				
Carl	Orringer	United States of America	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention					Session Moderator/Chair/Coordinator				
M. John	Chapman	France	Targeting risk factors with lifestyle					Session Moderator/Chair/Coordinator				
Frederick	Raal	South Africa	HOFH: new insights in therapeutic approaches					Session Moderator/Chair/Coordinator				
Frederick	Raal	South Africa	Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention					Session Moderator/Chair/Coordinator				
Filippo	Crea	Italy	Keynote Lecture						Advance Clinical Seminar Speaker			
Filippo	Crea	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Advance Clinical Seminar Speaker			
Ruth	Loos	Denmark	IAS/EAS joint session - What is the environment doing to our health?		Poster/Oral Presenter							
Arnold	von Eckardstein	Switzerland	Debate session - HDL: In search for a function		Poster/Oral Presenter							
Arnold	von Eckardstein	Switzerland	National Society President Meeting (NSPM)		Poster/Oral Presenter							
Arnold	von Eckardstein	Switzerland	General Assembly		Poster/Oral Presenter							
Oner	Ozdogan	Turkey	Imaging guided management					Session Moderator/Chair/Coordinator				

Oner	Ozdogan	Turkey	Poster Viewing session					Session Moderator/Chair/Coordinator				
Oner	Ozdogan	Turkey	Poster Viewing session					Session Moderator/Chair/Coordinator				
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?		Poster/Oral Presenter					Funded Research	Amarin	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?		Poster/Oral Presenter					Funded Research	Amarin	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Bayer	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Bayer	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Sanofi	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Sanofi	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Servier	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Funded Research	Servier	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	AstraZeneca	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	AstraZeneca	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	PhaseBio	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	PhaseBio	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Amgen	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Amgen	

Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	BMS	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	BMS	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Idorsia	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Idorsia	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Novartis	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Novartis	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Novo Nordisk	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Novo Nordisk	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Sanofi	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Sanofi	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Janssen	
Philippe Gabriel	Steg	France	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Janssen	
François	Mach	Switzerland	Implementation of the 2019 lipid guidelines-where are we now?							Session Moderator/Chair/Coordinator		
Marja-Riitta	Taskinen	Finland	Late breaker session 2							Session Moderator/Chair/Coordinator		

Peter	Libby	United States of America	Advanced clinical seminar: Changing face of atherosclerosis		Poster/Oral Presenter					1	Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron	
Peter	Libby	United States of America	Opening Ceremony incl. Anitschkow Lecture		Poster/Oral Presenter					1	Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron	

Peter	Libby	United States of America	Advanced clinical seminar: Changing face of atherosclerosis							Consultant/Advisory Board	Amgen, Caristo, Cartesian, CSL Behring, DalCor Pharmaceuticals, Dewpoint, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, and XBiotech, Inc.	
Peter	Libby	United States of America	Opening Ceremony incl. Anitschkow Lecture							Consultant/Advisory Board	Amgen, Caristo, Cartesian, CSL Behring, DalCor Pharmaceuticals, Dewpoint, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, and XBiotech, Inc.	
Peter	Libby	United States of America	Advanced clinical seminar: Changing face of atherosclerosis							1	XBiotech, Inc.	
Peter	Libby	United States of America	Opening Ceremony incl. Anitschkow Lecture							1	XBiotech, Inc.	
Peter	Libby	United States of America	Advanced clinical seminar: Changing face of atherosclerosis							Funded Research	Novartis	
Peter	Libby	United States of America	Opening Ceremony incl. Anitschkow Lecture							Funded Research	Novartis	
Kevin	Maki	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic						Session Moderator/Chair/Coordinator			

Pablo	Perel	United Kingdom	WHF Session 1: WHF Roadmap on Cholesterol update					Session Moderator/Chair/Cordinator				
Marina	Cuchel	United States of America	Saag session 14: Get rid of it: cholesterol efflux and reverse cholesterol transport		Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Regeneron	
Marina	Cuchel	United States of America	Apo B containing lipoproteins		Poster/Oral Presenter			Session Moderator/Chair/Cordinator		Funded Research	Regeneron	
Marina	Cuchel	United States of America	Saag session 14: Get rid of it: cholesterol efflux and reverse cholesterol transport							Funded Research	Regenxbio	
Marina	Cuchel	United States of America	Apo B containing lipoproteins							Funded Research	Regenxbio	
Marina	Cuchel	United States of America	Saag session 14: Get rid of it: cholesterol efflux and reverse cholesterol transport							Consultant/Advisory Board	Amryth	
Marina	Cuchel	United States of America	Apo B containing lipoproteins							Consultant/Advisory Board	Amryth	
Alberto	Corsini	Italy	Free Communication 1 - Genetics of Dyslipidemia					Session Moderator/Chair/Cordinator				
Alberto	Corsini	Italy	Late breaker session 1					Session Moderator/Chair/Cordinator				
Alexandros	Tselepis	Greece	Aging, dementia and stroke					Session Moderator/Chair/Cordinator				
Iris	Baumgartner	Switzerland	EAS Consensus activities		Poster/Oral Presenter							
Carlos	Cervantes	Spain	Why and how to implement early combination lipid lowering therapy		Poster/Oral Presenter							

Stephen	Nicholls	Australia	Imaging guided management							Consultant/Advisory Board	AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim	
Stephen	Nicholls	Australia	Imaging guided management							Funded Research	AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraREDx, Roche, Sanofi-Regeneron and LipoScience	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease						Session Moderator/Chair/Coordinator	Honoraria/Expenses	AMGEN	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle						Session Moderator/Chair/Coordinator	Honoraria/Expenses	AMGEN	
Evangelos	Liberopoulos	Greece	Poster Viewing session						Session Moderator/Chair/Coordinator	Honoraria/Expenses	AMGEN	
Evangelos	Liberopoulos	Greece	Poster Viewing session						Session Moderator/Chair/Coordinator	Honoraria/Expenses	AMGEN	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	ASTRAZENECA	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	ASTRAZENECA	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	ASTRAZENECA	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	ASTRAZENECA	



Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	BAYER	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	BAYER	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	BAYER	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	BAYER	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	CHIESI	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	CHIESI	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	CHIESI	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	CHIESI	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	NOVARTIS	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	NOVARTIS	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	NOVARTIS	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	NOVARTIS	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	NOVO NORDISK	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	NOVO NORDISK	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	NOVO NORDISK	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	NOVO NORDISK	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	SANOFI	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	SANOFI	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	SANOFI	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	SANOFI	
Evangelos	Liberopoulos	Greece	Saag session 02: Fresh perspectives of clinical vascular disease							Honoraria/Expenses	SERVIER	
Evangelos	Liberopoulos	Greece	Targeting risk factors with lifestyle							Honoraria/Expenses	SERVIER	

Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	SERVIER	
Evangelos	Liberopoulos	Greece	Poster Viewing session							Honoraria/Expenses	SERVIER	
Magdalena	Daccord	United Kingdom	WHF Session 2: Global FH						Speaker			
Magdalena	Daccord	United Kingdom	WHF Session 2: Global FH						Speaker			
Magdalena	Daccord	United Kingdom	FHSC Steering Committee Closed Annual Meeting Agenda						Speaker			
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update						Session Moderator/Chair/Coordinator	Consultant/Advisory Board	Amgen	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Sanofi	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Sanofi	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Roche	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Roche	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Novo Nordisk	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Novo Nordisk	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Ache	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Ache	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Amryt	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Amryt	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Hypera	

Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Hypera	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Amgen	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Amgen	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Astra Zeneca	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Astra Zeneca	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Ache	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Ache	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Novartis	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Novartis	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Novartis	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novartis	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Novo Nordisk	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Novo Nordisk	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	PTC	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	PTC	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	GETZ Pharma	

Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	GETZ Pharma	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Abbott	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Abbott	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Abbott	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Abbott	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Sanofi	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Sanofi	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Consultant/Advisory Board	Kowa	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Consultant/Advisory Board	Kowa	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Pfizer	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Pfizer	
Raul	Santos	Brazil	IAS/EAS joint session - What is the environment doing to our health?							Honoraria/Expenses	Eli Lilly	
Raul	Santos	Brazil	WHF Session 1: WHF Roadmap on Cholesterol update							Honoraria/Expenses	Eli Lilly	
Michal	Vrablík	Czech Republic	Industry Breakfast Session (Not Included In The Main Event CME/CPD Credit)		Poster/Oral Presenter							
Michal	Vrablík	Czech Republic	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia		Poster/Oral Presenter							

Michal	Vrablík	Czech Republic	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention		Poster/Oral Presenter							
Michal	Vrablík	Czech Republic	Industry Breakfast Session (Not Included In The Main Event CME/CPD Credit)		Poster/Oral Presenter							
Michal	Vrablík	Czech Republic	Industry Breakfast Session (Not Included In The Main Event CME/CPD Credit)		Poster/Oral Presenter							
Claudia	Monaco	United Kingdom	Saag session 24: Vascular calcification and remodeling		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Claudia	Monaco	United Kingdom	Modulating immune responses in atherosclerosis		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis					Session Moderator/Chair/Coordinator	Honoraria/Expenses	SANOFI		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)					Session Moderator/Chair/Coordinator	Honoraria/Expenses	SANOFI		
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Honoraria/Expenses	AMGEN		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)						Honoraria/Expenses	AMGEN		
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Honoraria/Expenses	AMRYT		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)						Honoraria/Expenses	AMRYT		
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Consultant/Advisory Board	AMARIN		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)						Consultant/Advisory Board	AMARIN		
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Honoraria/Expenses	MYLAN		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)						Honoraria/Expenses	MYLAN		
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis						Consultant/Advisory Board	ABBOTT		
Alberto	Zambon	Italy	National Society President Meeting (NSPM)						Consultant/Advisory Board	ABBOTT		

Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis							Honoraria/Expenses	PFIZER	
Alberto	Zambon	Italy	National Society President Meeting (NSPM)							Honoraria/Expenses	PFIZER	
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis							Honoraria/Expenses	ALFASIGMA	
Alberto	Zambon	Italy	National Society President Meeting (NSPM)							Honoraria/Expenses	ALFASIGMA	
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis							Honoraria/Expenses	DAIICHI SANKYO	
Alberto	Zambon	Italy	National Society President Meeting (NSPM)							Honoraria/Expenses	DAIICHI SANKYO	
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis							Honoraria/Expenses	SERVIER	
Alberto	Zambon	Italy	National Society President Meeting (NSPM)							Honoraria/Expenses	SERVIER	
Alberto	Zambon	Italy	Advanced clinical seminar: Changing face of atherosclerosis							Honoraria/Expenses	NOVARTIS	
Alberto	Zambon	Italy	National Society President Meeting (NSPM)							Honoraria/Expenses	NOVARTIS	
Jasmine	Gratton	United Kingdom	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter							
Ana	Medeiros	Portugal	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter							
Marie	Depuydt	Netherlands	Modulating immune responses in atherosclerosis		Poster/Oral Presenter							
Daniela	Baptista	Switzerland	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter							
Salim	Yusuf	Canada	Plenary 3: From lifestyle to designer therapies						Plenary speaker			
Azin	Kheirkhah	Austria	PCSK9 – new insights		Poster/Oral Presenter							
Federica	Galimberti	Italy	Poster Viewing session		Poster/Oral Presenter							
Federica	Galimberti	Italy	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter							

Paul	Ridker	United States of America	Plenary 3: From lifestyle to designer therapies		Poster/Oral Presenter			Session Moderator/Chair/Coordinator		Funded Research	Novartis, Kowa, Amarin, Pfizer, Esperion, and the NHLBI	I will describe an ongoing trial using ziltivekimab, a novel IL-6 inhibitor under investigation
Paul	Ridker	United States of America	Plenary 3: From lifestyle to designer therapies							Consultant/Advisory Board	Novartis, Flame, Agepha, AstraZeneca, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Upton, Omeicos, Health Outlook, Montai Health, New Amsterdam, Boehringer-Ingelheim, Angiowave, RTI; Horizon Therapeutics, Cardio Therapeutics	
Paul	Ridker	United States of America	Plenary 3: From lifestyle to designer therapies							Ownership/Equity Position	Angiowave	
Luis	Cardoso dos Santos	Switzerland	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter							
Urša	Šuštar	Slovenia	Poster Viewing session		Poster/Oral Presenter							
Urša	Šuštar	Slovenia	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter							
Karin	Bornfeldt	United States of America	Young fellows' session						Invited speaker			
Heinz	Drexel	Austria	Implementation of the 2019 lipid guidelines-where are we now?		Poster/Oral Presenter							
Khurram	Nasir	United States of America	IAS/EAS joint session - What is the environment doing to our health?		Poster/Oral Presenter							
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function		Poster/Oral Presenter					Honoraria/Expenses	Amgen	

Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Akcea	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	AstraZeneca	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Draupnir Bio	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Novartis	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Sanofi	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Silence Therapeutics	
Anne	Tybjærg-Hansen	Denmark	Debate session - HDL: In search for a function							Honoraria/Expenses	Regeneron	
Fernando	Lanas Zanetti	Chile	WHF Session 1: WHF Roadmap on Cholesterol update		Poster/Oral Presenter					Committee (CME, Research, other)		
Antonio J.	Vallejo-Vaz	Spain	Saag session 10: Do we succeed in dyslipidemia treatment in real world?		Poster/Oral Presenter					Funded Research	Participation in research grants to Imperial College London, UK, from Amgen, Regeneron and Daiichi Sankyo	
Antonio J.	Vallejo-Vaz	Spain	WHF Session 2: Global FH		Poster/Oral Presenter					Funded Research	Participation in research grants to Imperial College London, UK, from Amgen, Regeneron and Daiichi Sankyo	
Antonio J.	Vallejo-Vaz	Spain	Saag session 20: From bench to bedside in atherosclerosis		Poster/Oral Presenter					Funded Research	Participation in research grants to Imperial College London, UK, from Amgen, Regeneron and Daiichi Sankyo	
Antonio J.	Vallejo-Vaz	Spain	FHSC Steering Committee Closed Annual Meeting Agenda		Poster/Oral Presenter					Funded Research	Participation in research grants to Imperial College London, UK, from Amgen, Regeneron and Daiichi Sankyo	



Antonio J.	Vallejo-Vaz	Spain	FHSC Steering Committee Closed Annual Meeting Agenda		Poster/Oral Presenter					Funded Research	Participation in research grants to Imperial College London, UK, from Amgen, Regeneron and Daiichi Sankyo	
Antonio J.	Vallejo-Vaz	Spain	Saag session 10: Do we succeed in dyslipidemia treatment in real world?							Consultant/Advisory Board	Bayer, Regeneron and Radcliffe Cardiology	
Antonio J.	Vallejo-Vaz	Spain	WHF Session 2: Global FH							Consultant/Advisory Board	Bayer, Regeneron and Radcliffe Cardiology	
Antonio J.	Vallejo-Vaz	Spain	Saag session 20: From bench to bedside in atherosclerosis							Consultant/Advisory Board	Bayer, Regeneron and Radcliffe Cardiology	
Antonio J.	Vallejo-Vaz	Spain	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Bayer, Regeneron and Radcliffe Cardiology	
Antonio J.	Vallejo-Vaz	Spain	FHSC Steering Committee Closed Annual Meeting Agenda							Consultant/Advisory Board	Bayer, Regeneron and Radcliffe Cardiology	
Urh	Groselj	Slovenia	Poster Viewing session		Poster/Oral Presenter				Session Moderator/Chair/Coordinator	Lecturer		
Urh	Groselj	Slovenia	Poster Viewing session		Poster/Oral Presenter				Session Moderator/Chair/Coordinator	Lecturer		
Urh	Groselj	Slovenia	WHF Session 2: Global FH		Poster/Oral Presenter				Session Moderator/Chair/Coordinator	Lecturer		
Amita	Arora	Finland	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter							
Aldo Pietro	Maggioni	Italy	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?		Poster/Oral Presenter							
Preston	Mason	United States of America	Saag session 18: The cruciality of endothelial cells		Poster/Oral Presenter					Funded Research	Amarin	
Preston	Mason	United States of America	Poster Viewing session		Poster/Oral Presenter					Funded Research	Amarin	

Preston	Mason	United States of America	Poster Viewing session		Poster/Oral Presenter					Funded Research	Amarin	
Preston	Mason	United States of America	Poster Viewing session		Poster/Oral Presenter					Funded Research	Amarin	
Preston	Mason	United States of America	Poster Viewing session		Poster/Oral Presenter					Funded Research	Amarin	
Preston	Mason	United States of America	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?		Poster/Oral Presenter					Funded Research	Amarin	
Preston	Mason	United States of America	Saag session 18: The cruciality of endothelial cells							Consultant/Advisory Board	Amarin	
Preston	Mason	United States of America	Poster Viewing session							Consultant/Advisory Board	Amarin	
Preston	Mason	United States of America	Poster Viewing session							Consultant/Advisory Board	Amarin	
Preston	Mason	United States of America	Poster Viewing session							Consultant/Advisory Board	Amarin	
Preston	Mason	United States of America	Poster Viewing session							Consultant/Advisory Board	Amarin	
Preston	Mason	United States of America	Omega 3 fatty acids in cardiovascular prevention - Where do we stand?							Consultant/Advisory Board	Amarin	
Michael	Papadakis	United Kingdom	Targeting risk factors with lifestyle		Poster/Oral Presenter					Consultant/Advisory Board	Bristol Myers Squibb	
Michael	Papadakis	United Kingdom	Targeting risk factors with lifestyle							Funded Research	Cardiac Risk in the Young	
Elena	Olmastroni	Italy	Poster Viewing session		Poster/Oral Presenter							
Elena	Olmastroni	Italy	Late breaker session 2		Poster/Oral Presenter							
Noemi	Rotllan	Spain	Late breaker session 2		Poster/Oral Presenter							
Jiao	Luo	Denmark	Late breaker session 1		Poster/Oral Presenter							
Muriel	Laffargue	France	Late breaker session 2		Poster/Oral Presenter							
Kanika	Dharmayat	United Kingdom	Late breaker session 1		Poster/Oral Presenter							
Johanna	Schachtl-Riess	Austria	Late breaker session 1		Poster/Oral Presenter							
Rubina	Tabassum	Finland	Late breaker session 1		Poster/Oral Presenter							

Marina	Habib	France	Saag session 14: Get rid of it: cholesterol efflux and reverse cholesterol transport		Poster/Oral Presenter							
Marina	Habib	France	Late breaker session 2		Poster/Oral Presenter							
Ziad	Mallat	United Kingdom	Modulating immune responses in atherosclerosis		Poster/Oral Presenter				NA			
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic		Poster/Oral Presenter					Funded Research	Amgen	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	Novartis	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	Arrowhead	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	Sanofi	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Funded Research	IONIS	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	AKCEA	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Regeneron	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							1	New Amsterdam	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Esperion	
Anne	Goldberg	United States of America	NLA/EAS joint session - Primordial prevention: The neglected topic							Consultant/Advisory Board	Novartis	
Camilla	Johannesen	Denmark	Apo B containing lipoproteins		Poster/Oral Presenter							
Goo Taeg	Oh	Korea, Republic of	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter							
Émilie	Gobeil	Canada	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter							
Felix	Jansen	Germany	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter							
Liv	Nordestgaard	Denmark	Aging, dementia and stroke		Poster/Oral Presenter							

Harshvardhan	Khare	Denmark	Atherothrombosis and myeloid cells	Scientific/Education Planning Committee	Poster/Oral Presenter								
Yara	Azar	France	PCSK9 – new insights		Poster/Oral Presenter								
Peter	Thomas	Denmark	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter								
Manuela	Casula	Italy	Apo B containing lipoproteins		Poster/Oral Presenter								
Helene	Gellert-Kristensen	Denmark	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter								
Emiel	van der Vorst	Germany	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter								
Veronika	Myasoedova	Italy	Imaging guided management		Poster/Oral Presenter								
Nuria	Matesanz	Spain	Atherothrombosis and myeloid cells		Poster/Oral Presenter								
Hana	Totary-Jain	United States of America	New World of targeted therapies (targets, delivery systems, new molecules)		Poster/Oral Presenter								
Marta	Amorós-Pérez	Spain	Poster Viewing session		Poster/Oral Presenter								
Marta	Amorós-Pérez	Spain	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter								
David	Burgner	Australia	Environment and cardiovascular risk		Poster/Oral Presenter								
Horea-Laurentiu	Onea	Romania	Imaging guided management		Poster/Oral Presenter								
Cecilia	Bonfiglio	Germany	Modulating immune responses in atherosclerosis		Poster/Oral Presenter								
Andrea	Baragetti	Italy	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter								
Dimitrios	Tsiantoulas	Austria	Modulating immune responses in atherosclerosis		Poster/Oral Presenter								
Mei Shan	Ong	Singapore	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter								
Silvia	Di Maio	Austria	Atherothrombosis and myeloid cells		Poster/Oral Presenter								
Sabine	Bauer	Germany	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter								
Alexis	Hofherr	Sweden	New World of targeted therapies (targets, delivery systems, new molecules)		Poster/Oral Presenter					Employee	AstraZeneca		
Reindert	Oostveen	Netherlands	Imaging guided management		Poster/Oral Presenter								

bidda	Rolin	Denmark	PCSK9 – new insights		Poster/Oral Presenter						Employee	Novo Nordisk A/S	Pre-clinical effects of evinacumab and alirocumab and a peptide in development from Novo Nordisk A/S
bidda	Rolin	Denmark	PCSK9 – new insights								Stock Options	Novo Nordisk A/S	
Hyung Joon	Joo	Korea, Republic of	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter								
Hasanga	Manikpurage	Canada	Aging, dementia and stroke		Poster/Oral Presenter								
Sabrina	Pagano	Switzerland	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter								
Florian	Mourre	France	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter								
Floriana	Farina	Germany	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter								
Bingni	Chen	Germany	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter								
Seyed Soheil	Saeedi Saravi	Switzerland	Endothelial cell biology in atherosclerosis		Poster/Oral Presenter								
Zivile	Girkantaite	Lithuania	Apo B containing lipoproteins		Poster/Oral Presenter								
Raquel	Guillamat-Prats	Spain	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter								
Fabrizia	Bonacina	Italy	Saag session 07: Cell talk time: receptors and intracellular trafficking		Poster/Oral Presenter								
Fabrizia	Bonacina	Italy	Modulating immune responses in atherosclerosis		Poster/Oral Presenter								
Olivier	Mansier	France	Aging, dementia and stroke		Poster/Oral Presenter	Board of Directors							
Sanne	Maas	Germany	Modulating immune responses in atherosclerosis		Poster/Oral Presenter								
Lorenzo	Da Dalt	Italy	PCSK9 – new insights		Poster/Oral Presenter								
Lorenzo	Da Dalt	Italy	Poster Viewing session		Poster/Oral Presenter								

Laura	D'Erasmus	Italy	Saag session 08: Optimize treatment in familial hypercholesterolemia		Poster/Oral Presenter					Honoraria/Expenses	Amryt	
Laura	D'Erasmus	Italy	New World of targeted therapies (targets, delivery systems,new molecules)		Poster/Oral Presenter					Honoraria/Expenses	Amryt	
Laura	D'Erasmus	Italy	Saag session 08: Optimize treatment in familial hypercholesterolemia							Honoraria/Expenses	SOBI	
Laura	D'Erasmus	Italy	New World of targeted therapies (targets, delivery systems,new molecules)							Honoraria/Expenses	SOBI	
Laura	D'Erasmus	Italy	Saag session 08: Optimize treatment in familial hypercholesterolemia							Consultant/Advisory Board	Amryt	
Laura	D'Erasmus	Italy	New World of targeted therapies (targets, delivery systems,new molecules)							Consultant/Advisory Board	Amryt	
Suzanne	van Wouw	Netherlands	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter					Ownership/Equity Position	The Struggling Scientists	
Jan	Kuivenhoven	Netherlands	Plenary 2: Lipoproteins revisited: What has changed ?		Poster/Oral Presenter							
Rossella	Bellini	Italy	Free Communication 1 - Genetics of Dyslipidemia		Poster/Oral Presenter							
Pauline	Puylaert	Belgium	Smooth muscle cell biology and plaque stability		Poster/Oral Presenter							
Pauline	Puylaert	Belgium	Saag session 11: How cells talk? Smooth muscle cells and macrophages		Poster/Oral Presenter							
Antonio	GALLO	France	Imaging guided management		Poster/Oral Presenter					Honoraria/Expenses	AMGEN	
Antonio	GALLO	France	Imaging guided management							Honoraria/Expenses	SANOFI	
Antonio	GALLO	France	Imaging guided management							Consultant/Advisory Board	ORGANON	
Antonio	GALLO	France	Imaging guided management							Honoraria/Expenses	NOVARTIS	
Antonio	GALLO	France	Imaging guided management							Honoraria/Expenses	AKCEA	
Antonio	GALLO	France	Imaging guided management							Consultant/Advisory Board	AMRYT	
Antonio	GALLO	France	Imaging guided management							Honoraria/Expenses	MSD	
Antonio	GALLO	France	Imaging guided management							Honoraria/Expenses	VIATRIS	

Tess	Yntema	Netherlands	Environment and cardiovascular risk		Poster/Oral Presenter								
Anna	Palmiotti	Netherlands	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter								
Shifa	Jebari Benslaiman	Spain	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter								
Florentina	Porsch	Austria	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter								
Kévin	CHEMELLO	France	Aging, dementia and stroke		Poster/Oral Presenter								
Paolo	Raggi	Canada	Poster Viewing session		Poster/Oral Presenter								
Paolo	Raggi	Canada	Imaging guided management		Poster/Oral Presenter								
Dianne	van Dam-Nolen	Netherlands	Aging, dementia and stroke		Poster/Oral Presenter								
Ilenia	Minicocci	Italy	Apo B containing lipoproteins		Poster/Oral Presenter								
Bianca	Papotti	Italy	PCSK9 – new insights		Poster/Oral Presenter								
Bianca	Papotti	Italy	Saag session 17: Think outside the box: on cognition and PCSK9		Poster/Oral Presenter								
Giuseppe	Della Pepa	Italy	Poster Viewing session		Poster/Oral Presenter								
Giuseppe	Della Pepa	Italy	Cardiometabolic Risk and Ectopic Fat		Poster/Oral Presenter								
Philippe	Boucher	France	Free Communication 2 - New insights into lipoprotein metabolism, vascular biology and atherosclerosis		Poster/Oral Presenter								
Julia	Ramírez	United Kingdom	Non-classical risk factors: Transitioning from association to causality		Poster/Oral Presenter								
Willemien	van Zwol	Netherlands	Apo B containing lipoproteins		Poster/Oral Presenter								
Giulia	Chiesa	Italy	Non-classical risk factors: Transitioning from association to causality							Session Moderator/Chair/Coordinator			
Giulia	Chiesa	Italy	Poster Viewing session							Session Moderator/Chair/Coordinator			

Marianne	Benn	Denmark	Atherothrombosis and myeloid cells	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	Reimagining population health- the time is now	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	General Assembly	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	General Assembly	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	General Assembly	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	General Assembly	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Marianne	Benn	Denmark	General Assembly	Scientific/Education Planning Committee			Committee (CME, Research, other)	Session Moderator/Chair/Coordinator				
Ruth	Frikke-Schmidt	Denmark	Aging, dementia and stroke		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Ruth	Frikke-Schmidt	Denmark	Saag session 22: Big data of CVD risk and treatments		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Alberto	Mello e Silva	Portugal	Cardiometabolic Risk and Ectopic Fat					Session Moderator/Chair/Coordinator				
Philippe	Moulin	France	Cardiometabolic Risk and Ectopic Fat					Session Moderator/Chair/Coordinator		Consultant/Advisory Board	ionis pharmaceutical	
Philippe	Moulin	France	HOFH: new insights in therapeutic approaches					Session Moderator/Chair/Coordinator		Consultant/Advisory Board	ionis pharmaceutical	
Philippe	Moulin	France	Cardiometabolic Risk and Ectopic Fat							Funded Research	AKcea	
Philippe	Moulin	France	HOFH: new insights in therapeutic approaches							Funded Research	AKcea	
Philippe	Moulin	France	Cardiometabolic Risk and Ectopic Fat							Honoraria/Expenses	Amgen	



Philippe	Moulin	France	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Amgen	
Philippe	Moulin	France	Cardiometabolic Risk and Ectopic Fat							Honoraria/Expenses	Novo Nordisk	
Philippe	Moulin	France	HOFH: new insights in therapeutic approaches							Honoraria/Expenses	Novo Nordisk	
Philippe	Moulin	France	Cardiometabolic Risk and Ectopic Fat							Consultant/Advisory Board	Pfizer	
Philippe	Moulin	France	HOFH: new insights in therapeutic approaches							Consultant/Advisory Board	Pfizer	
Ulf	Landmesser	Germany	Imaging guided management						Session Moderator/Chair/Cordinator	Funded Research	Amgen, Novartis, Bayer	
Ulf	Landmesser	Germany	Imaging guided management							Consultant/Advisory Board	Novartis, Sanofi, Amgen, Bayer, Daiichi Sankyo, Pfizer, Boeringer	
Ulf	Landmesser	Germany	Imaging guided management							Honoraria/Expenses	Novartis, Sanofi, Amgen, Bayer, DaiichiSankyo, Pfizer, AstraZeneca	
Henry	Ginsberg	United States of America	Late breaker session 1						Session Moderator/Chair/Cordinator			
Ulrich	Laufs	Germany	Late breaker session 2		Poster/Oral Presenter				Session Moderator/Chair/Cordinator	Consultant/Advisory Board	Amgen, Daiichi-Sankyo, Novartis, Sanofi	
Ulrich	Laufs	Germany	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia		Poster/Oral Presenter				Session Moderator/Chair/Cordinator	Consultant/Advisory Board	Amgen, Daiichi-Sankyo, Novartis, Sanofi	
Ulrich	Laufs	Germany	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention		Poster/Oral Presenter				Session Moderator/Chair/Cordinator	Consultant/Advisory Board	Amgen, Daiichi-Sankyo, Novartis, Sanofi	
Ulrich	Laufs	Germany	National Society President Meeting (NSPM)		Poster/Oral Presenter				Session Moderator/Chair/Cordinator	Consultant/Advisory Board	Amgen, Daiichi-Sankyo, Novartis, Sanofi	

Ulrich	Laufs	Germany	Late breaker session 2							Honoraria/Expenses	Amgen, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, Daiichi-Sankyo, Lilly, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi	
Ulrich	Laufs	Germany	ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia							Honoraria/Expenses	Amgen, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, Daiichi-Sankyo, Lilly, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi	
Ulrich	Laufs	Germany	Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention							Honoraria/Expenses	Amgen, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, Daiichi-Sankyo, Lilly, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi	
Ulrich	Laufs	Germany	National Society President Meeting (NSPM)							Honoraria/Expenses	Amgen, AstraZeneca, Bayer, Berlin-Chemie, Boehringer, Daiichi-Sankyo, Lilly, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi	
Laurent	Yvan-Charvet	France	Saag session 01: Regulation of macrophages in atherosclerosis						Session Moderator/Chair/Coordinator			
Laurent	Yvan-Charvet	France	Young fellows' session						Session Moderator/Chair/Coordinator			

Gerard	Pasterkamp	Netherlands	Modulating immune responses in atherosclerosis					Session Moderator/Chair/Coordinator				
Francisco	Araújo	Portugal	Saag session 06: Novel perspectives of diabetes		Poster/Oral Presenter							
Francisco	Araújo	Portugal	Poster Viewing session		Poster/Oral Presenter							
Francisco	Araújo	Portugal	Saag session 28: Latest evidence from epidemiology		Poster/Oral Presenter							
Jeffrey	Kroon	Netherlands	Saag session 18: The cruciality of endothelial cells		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Jeffrey	Kroon	Netherlands	Young fellows' session		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Chrysoula	Boutari	Greece	Saag session 19: Controlling inflammation in atherosclerosis		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Chrysoula	Boutari	Greece	Young fellows' session		Poster/Oral Presenter			Session Moderator/Chair/Coordinator				
Paolo	Parini	Sweden	Endothelial cell biology in atherosclerosis					Session Moderator/Chair/Coordinator		Royalties/Patent	Lipoprotein Research Stockholm AB	
Paolo	Parini	Sweden	Saag session 13: The culprit? Fatty liver					Session Moderator/Chair/Coordinator		Royalties/Patent	Lipoprotein Research Stockholm AB	
Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis					Session Moderator/Chair/Coordinator		Honoraria/Expenses	Bayer	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells					Session Moderator/Chair/Coordinator		Honoraria/Expenses	Bayer	
Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis							Honoraria/Expenses	Sanofi	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells							Honoraria/Expenses	Sanofi	
Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis							Honoraria/Expenses	Novartis	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells							Honoraria/Expenses	Novartis	
Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis							Consultant/Advisory Board	Novartis	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells							Consultant/Advisory Board	Novartis	
Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis							Consultant/Advisory Board	Sanofi	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells							Consultant/Advisory Board	Sanofi	

Lina	Badimon	Spain	Endothelial cell biology in atherosclerosis						Consultant/Advisory Board	Pfizer	
Lina	Badimon	Spain	Atherothrombosis and myeloid cells						Consultant/Advisory Board	Pfizer	
Marat	Ezhov	Russian Federation	PCSK9 – new insights		Poster/Oral Presenter			Session Moderator/Chair/Coordinator			
Marat	Ezhov	Russian Federation	Saag session 26: The significance of Lp(a)		Poster/Oral Presenter			Session Moderator/Chair/Coordinator			
Marat	Ezhov	Russian Federation	Poster Viewing session		Poster/Oral Presenter			Session Moderator/Chair/Coordinator			
Marcello	Arca	Italy	Apo B containing lipoproteins				Committee (CME, Research, other)				
Marcello	Arca	Italy	Poster Viewing session				Committee (CME, Research, other)				
Marcello	Arca	Italy	HOFH: new insights in therapeutic approaches				Committee (CME, Research, other)				
Nathan	Wong	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)					Session Moderator/Chair/Coordinator	Funded Research	Novartis, Novo Nordisk	
Nathan	Wong	United States of America	New World of targeted therapies (targets, delivery systems,new molecules)						Consultant/Advisory Board	Amgen, Novartis	
Franco	Bernini	Italy	New World of targeted therapies (targets, delivery systems,new molecules)					Session Moderator/Chair/Coordinator			